Form 4: Alaunos Therapeutics CEO Acquires Shares

Alaunos Therapeutics CEO Holger Weis acquired 3,880 shares of common stock for $2.26 per share, issued in lieu of net salary.

Summary

• Holger Weis, Chief Executive Officer of Alaunos Therapeutics, Inc., acquired 3,880 shares of common stock on June 30, 2026.
• The shares were issued in lieu of net salary and the transaction price was $2.26 per share.
• Following this transaction, Weis beneficially owns 16,552 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents an insider purchase, but it's tied to compensation rather than an open market purchase.

Positives

• CEO's acquisition of shares indicates confidence in the company's future.
• Issuance of shares in lieu of salary can be a cost-saving measure for the company.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider stock purchases, especially by CEOs, can be interpreted as a positive signal of management's belief in the company's valuation and future prospects within the biotechnology sector.

Stakeholder Impact

• Shareholders may view the CEO's acquisition of shares positively, signaling confidence in the company's future.
• Employees may see this as a sign of management's commitment, especially as the shares were issued in lieu of salary.

Key Dates

Keywords

Alaunos Therapeutics, TCRT, Form 4, Insider Transaction, Common Stock, CEO, Beneficial Ownership